Complement Therapeutics Doses First Patient in Opti-GAIN Study for AMD-Related Vision Loss Complement Therapeutics has initiated its groundbreaking Phase I/II Opti-GAIN study, with the first patient dosed with CTx001 for Geographic Atrophy related to AMD.

Complement Therapeutics Doses First Patient in Opti-GAIN Study for AMD-Related Vision Loss #Germany #Munich #Geographic_Atrophy #Complement_Therapeutics #CTx001

Complement Therapeutics Receives FDA Fast Track for CTx001 to Treat AMD-Related Geographic Atrophy Complement Therapeutics has been granted Fast Track designation from the FDA for its gene therapy CTx001 aimed at treating Geographic Atrophy linked to AMD, addressing unmet medical needs.

Complement Therapeutics Receives FDA Fast Track for CTx001 to Treat AMD-Related Geographic Atrophy #Germany #Munich #AMD #Complement_Therapeutics #CTx001

Complement Therapeutics Gets FDA Approval for CTx001 Clinical Trial Targeting Geographic Atrophy in AMD Patients Complement Therapeutics has received FDA clearance for its investigational gene therapy CTx001, aimed at treating geographic atrophy caused by AMD, in an upcoming clinical trial.

Complement Therapeutics Gets FDA Approval for CTx001 Clinical Trial Targeting Geographic Atrophy in AMD Patients #USA #Munich #AMD #Complement_Therapeutics #CTx001